Leukocyte interleukin - CEL-SCI

Drug Profile

Leukocyte interleukin - CEL-SCI

Alternative Names: BC-IL; Buffy coat interleukins - CEL-SCI; Interleukin-2 cocktail - CEL-SCI; Multikine

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator CEL-SCI Corporation
  • Developer CEL-SCI Corporation; Ergomed; Naval Medical Research Center; Orient Europharma; Teva Pharmaceutical Industries
  • Class Antineoplastics; Granulocyte-macrophage colony-stimulating factors; Interferons; Interleukins
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cervical dysplasia; Condylomata acuminata
  • Suspended Head and neck cancer
  • Discontinued Breast cancer; HIV infections; Prostate cancer

Most Recent Events

  • 09 Mar 2017 CEL-SCI has patent protection for leukocyte interleukin in China
  • 16 Dec 2016 CEL-SCI receives incomplete response to hold letter from the FDA for leukocyte interleukin in Head and neck cancer (CEL-SCI, Form 8K February 2017)
  • 26 Sep 2016 Suspended - Phase-III for Head and neck cancer (First-line therapy, Neoadjuvant therapy) in USA, Poland, India, Poland, Canada, Israel, Russia, Taiwan, Croatia, Hungary, Bosnia-Herzegovina, Serbia, Ukraine, Austria, United Kingdom, France, Sri Lanka, Turkey, Thailand, Italy, Spain, Malaysia, Romania, Belarus (Perilesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top